drugset / Trial / NCT01952444

Safety, Tolerability and PK of Intravenous (IV) ETI-204 Alone and in Presence of Ciprofloxacin in Adult Volunteers

NCT01952444

Phase 1 Completed 40 enrolled Elusys Therapeutics
RandomizedParallel-groupOpen-labelOther

Summary

Evaluate the safety, tolerability and pharmacokinetics (PK) of intravenous (IV) ETI-204 alone and in the presence of IV and oral ciprofloxacin

Timeline

Start
2013-10-29
Primary completion
2014-04-09
Completion
2014-04-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Ciprofloxacin Small molecule 750 mg Intravenous
Subject Obiltoxaximab Monoclonal antibody 16 mg/kg Intravenous

Indications